Illumina NextSeq550 Whole Genome Sequencing Insturment

The Food and Drug Administration intends to make a sole source award for an Illumina Nextseq550 instrument to support CFSAN's efforts to evaluate microbial and viral communities within complex food matrices using Next Generation Sequencing (NGS). The FDA uses Illumina's proprietary method of sequencing which enables the parallel sequencing and is required to maintain consistent sequencing methods. We intend to make a sole source award to: Illumina, Inc., 5200 Illumina Way San Diego, CA 92122 In accordance with FAR 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements. This notice of intent is not a request for competitive quotes. However, all responsible sources may submit a capability statement within five (5) days after the publication of this synopsis which shall be considered by the agency. Responses received after 5 days or without the required information may not be considered. For information concerning this acquisition contact: Susan Bechtel Contract Specialist Susan.Bechtel@fda.hhs.gov No phone calls please A determination by the Government not to compete because of information received is solely within the discretion of the Government. Information received will normally be considered solely for determining whether to conduct a competitive procurement.